{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:44:18Z","timestamp":1792111458993,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Distinguishing between tumor progression and radiation necrosis during brain tumor follow-up is challenging. Advanced MR imaging techniques, such as perfusion, diffusion-weighted imaging (DWI), and spectroscopy, can help differentiate between these conditions. In our clinic, we established a novel technique, the rapid washout and late-enhancement map. This study investigated the value of this map in distinguishing true progression from radiation necrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with a histologically confirmed initial diagnosis of glioblastoma, high-grade astrocytoma, primary central nervous system lymphoma, or brain metastasis who were undergoing radiochemotherapy and participated in our MRI protocol, including MR perfusion and rapid washout imaging, between January 1, 2024, and December 31, 2025, were included in the study.<\/jats:p>\n                    <jats:p>We volumetrically measured late enhancement and washout in brain tumors at all follow-up examinations and analyzed the resulting volumes. Additionally, we evaluated diffusion-weighted imaging and MR perfusion images.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 33 patients (25 with glioblastoma, two with astrocytoma grade 4, two with astrocytoma grade 3, one with CNS lymphoma, and three with brain metastasis) were included. Diagnostic confirmation was obtained by histopathological assessment in 20 patients, MRI follow-up in 13 patients, with additional fluorodeoxyglucose-positron emission tomography in two.<\/jats:p>\n                    <jats:p>Among these patients, 23 were diagnosed with tumor recurrence, four with mixed pathology comprising \u201cradiation necrosis with scattered active tumor cells\u201d, and six with radiation necrosis. The mean washout ratio (\u00b1 standard deviation) was 31 \u00b1 18 % for progressive disease, 35 \u00b1 20 % for mixed pathology, and 10 \u00b1 7 % for radiation necrosis, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The washout ratio can enhance the differentiation between recurrent tumor growth and radiation necrosis during post-treatment monitoring of malignant brain tumors. As MR perfusion can yield inconclusive results in this setting, the proposed method offers complementary information that supports initial diagnostic decision making. Diagnostic discrimination may be strengthened by combining the relative cerebral blood volume with washout ratio analysis, rather than relying on a single imaging marker.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-17170-0","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:47:43Z","timestamp":1792108063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Late enhancement and washout maps for distinguishing tumor progression from radiation necrosis in malignant brain tumors: an exploratory study"],"prefix":"10.1186","volume":"26","author":[{"given":"Eya","family":"Khadhraoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Klebingat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I Erol","family":"Sandalcioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Arndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Behme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Peter","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2147-9797","authenticated-orcid":false,"given":"Sebastian Johannes","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"17170_CR1","doi-asserted-by":"publisher","first-page":"e22261","DOI":"10.1002\/ddr.22261","volume":"85","author":"S Satish","year":"2024","unstructured":"Satish S, Athavale M, Kharkar PS. Targeted therapies for Glioblastoma multiforme (GBM): State-of\u2010the\u2010art and future prospects. Drug Dev Res. 2024;85:e22261. https:\/\/doi.org\/10.1002\/ddr.22261.","journal-title":"Drug Dev Res"},{"key":"17170_CR2","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/S1470-2045(14)70011-7","volume":"15","author":"M Weller","year":"2014","unstructured":"Weller M, Van Den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15:e395\u2013403. https:\/\/doi.org\/10.1016\/S1470-2045(14)70011-7.","journal-title":"Lancet Oncol"},{"key":"17170_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/neuonc\/now241","volume":"19","author":"R Soffietti","year":"2017","unstructured":"Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-Oncol. 2017;19:162\u201374. https:\/\/doi.org\/10.1093\/neuonc\/now241.","journal-title":"Neuro-Oncol"},{"key":"17170_CR4","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY, Van Den Bent M, Youssef G, Cloughesy TF, Ellingson BM, Weller M, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol. 2023;41:5187\u201399. https:\/\/doi.org\/10.1200\/JCO.23.01059.","journal-title":"J Clin Oncol"},{"key":"17170_CR5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/CCO.0000000000001077","volume":"36","author":"F Sanvito","year":"2024","unstructured":"Sanvito F, Castellano A, Cloughesy TF, Wen PY, Ellingson BM. RANO 2.0 criteria: concepts applicable to the neuroradiologist\u2019s clinical practice. Curr Opin Oncol. 2024;36:536\u201344. https:\/\/doi.org\/10.1097\/CCO.0000000000001077.","journal-title":"Curr Opin Oncol"},{"key":"17170_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/6828396","volume":"2018","author":"A Zikou","year":"2018","unstructured":"Zikou A, Sioka C, Alexiou GA, Fotopoulos A, Voulgaris S, Argyropoulou MI, Radiation Necrosis. Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas. Contrast Media Mol Imaging. 2018;2018:1\u20136. https:\/\/doi.org\/10.1155\/2018\/6828396.","journal-title":"Contrast Media Mol Imaging"},{"key":"17170_CR7","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s11604-025-01821-6","volume":"43","author":"A Sakata","year":"2025","unstructured":"Sakata A, Fushimi Y, Oshima S, Uto M, Mineharu Y, Nakajima S, et al. RANO 2.0: critical updates and practical considerations for radiological assessment in neuro-oncology. Jpn J Radiol. 2025;43:1557\u201374. https:\/\/doi.org\/10.1007\/s11604-025-01821-6.","journal-title":"Jpn J Radiol"},{"key":"17170_CR8","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3390\/biomedicines13071778","volume":"13","author":"S Reddy","year":"2025","unstructured":"Reddy S, Lung T, Muniyappa S, Hadley C, Templeton B, Fritz J, et al. Radiomics and Radiogenomics in Differentiating Progression, Pseudoprogression, and Radiation Necrosis in Gliomas. Biomedicines. 2025;13:1778. https:\/\/doi.org\/10.3390\/biomedicines13071778.","journal-title":"Biomedicines"},{"key":"17170_CR9","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1055\/a-2719-5058","volume":"45","author":"E Coffee","year":"2025","unstructured":"Coffee E, Elshiekh C, Budhu JA. Imaging in Neuro-oncology. Semin Neurol. 2025;45:654\u201365. https:\/\/doi.org\/10.1055\/a-2719-5058.","journal-title":"Semin Neurol"},{"key":"17170_CR10","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.1016\/S1470-2045(25)00193-7","volume":"26","author":"N Galldiks","year":"2025","unstructured":"Galldiks N, Lohmann P, Aboian M, Barajas RF, Breen WG, Ivanidze J, et al. Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas. Lancet Oncol. 2025;26:e436\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(25)00193-7.","journal-title":"Lancet Oncol"},{"key":"17170_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.acra.2009.08.014","volume":"17","author":"T Engelhorn","year":"2010","unstructured":"Engelhorn T, Schwarz MA, Eyupoglu IY, Kloska SP, Struffert T, Doerfler A. Dynamic Contrast Enhancement of Experimental Glioma. Acad Radiol. 2010;17:188\u201393. https:\/\/doi.org\/10.1016\/j.acra.2009.08.014.","journal-title":"Acad Radiol"},{"key":"17170_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/RLI.0b013e31819ba711","volume":"44","author":"UI Attenberger","year":"2009","unstructured":"Attenberger UI, Runge VM, Jackson CB, Baumann S, Birkemeier K, Michaely HJ, et al. Comparative Evaluation of Lesion Enhancement Using 1\u00a0M Gadobutrol vs. 2 Conventional Gadolinium Chelates, All at a Dose of 0.1 mmol\/kg, in a Rat Brain Tumor Model at 3 T. Invest Radiol. 2009;44:251\u20136. https:\/\/doi.org\/10.1097\/RLI.0b013e31819ba711.","journal-title":"Invest Radiol"},{"key":"17170_CR13","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1186\/s12885-024-12909-z","volume":"24","author":"E Khadhraoui","year":"2024","unstructured":"Khadhraoui E, Schmidt L, Klebingat S, Schwab R, Hern\u00e1ndez-Dur\u00e1n S, Gihr G, et al. Comparison of a new MR rapid wash-out map with MR perfusion in brain tumors. BMC Cancer. 2024;24:1139. https:\/\/doi.org\/10.1186\/s12885-024-12909-z.","journal-title":"BMC Cancer"},{"key":"17170_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00259-018-4207-9","volume":"46","author":"I Law","year":"2019","unstructured":"Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM\/EANO\/RANO practice guidelines\/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46:540\u201357. https:\/\/doi.org\/10.1007\/s00259-018-4207-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"17170_CR15","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3174\/ajnr.A8565","volume":"46","author":"C Zhou","year":"2025","unstructured":"Zhou C, Kou Y, Zhou W, Zhao W, Fan Z, Jiao Y, et al. Diagnostic Value of PET Tracers in Differentiating Glioma Tumor Recurrence from Treatment-Related Changes: A Systematic Review and Meta-Analysis. Am J Neuroradiol. 2025;46:758\u201365. https:\/\/doi.org\/10.3174\/ajnr.A8565.","journal-title":"Am J Neuroradiol"},{"key":"17170_CR16","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncol. 2021;23:1231\u201351. https:\/\/doi.org\/10.1093\/neuonc\/noab106.","journal-title":"Neuro-Oncol"},{"key":"17170_CR17","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.neuroimage.2011.09.015","volume":"62","author":"M Jenkinson","year":"2012","unstructured":"Jenkinson M, Beckmann CF, Behrens TEJ, Woolrich MW, Smith SM. FSL NeuroImage. 2012;62:782\u201390. https:\/\/doi.org\/10.1016\/j.neuroimage.2011.09.015.","journal-title":"FSL NeuroImage"},{"key":"17170_CR18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1006\/nimg.2002.1132","volume":"17","author":"M Jenkinson","year":"2002","unstructured":"Jenkinson M, Bannister P, Brady M, Smith S. Improved Optimization for the Robust and Accurate Linear Registration and Motion Correction of Brain Images. NeuroImage. 2002;17:825\u201341. https:\/\/doi.org\/10.1006\/nimg.2002.1132.","journal-title":"NeuroImage"},{"key":"17170_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1361-8415(01)00036-6","volume":"5","author":"M Jenkinson","year":"2001","unstructured":"Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001;5:143\u201356. https:\/\/doi.org\/10.1016\/S1361-8415(01)00036-6.","journal-title":"Med Image Anal"},{"key":"17170_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.neuroimage.2009.06.060","volume":"48","author":"DN Greve","year":"2009","unstructured":"Greve DN, Fischl B. Accurate and robust brain image alignment using boundary-based registration. NeuroImage. 2009;48:63\u201372. https:\/\/doi.org\/10.1016\/j.neuroimage.2009.06.060.","journal-title":"NeuroImage"},{"key":"17170_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04573-x","author":"SJ M\u00fcller","year":"2024","unstructured":"M\u00fcller SJ, Khadhraoui E, Ganslandt O, Henkes H, Gihr GA. MRI Treatment Response Assessment Maps (TRAMs) for differentiating recurrent glioblastoma from radiation necrosis. J Neurooncol. 2024. https:\/\/doi.org\/10.1007\/s11060-024-04573-x.","journal-title":"J Neurooncol"},{"key":"17170_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3174\/ajnr.A1362","volume":"30","author":"RF Barajas","year":"2009","unstructured":"Barajas RF, Chang JS, Sneed PK, Segal MR, McDermott MW, Cha S. Distinguishing Recurrent Intra-Axial Metastatic Tumor from Radiation Necrosis Following Gamma Knife Radiosurgery Using Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging. Am J Neuroradiol. 2009;30:367\u201372. https:\/\/doi.org\/10.3174\/ajnr.A1362.","journal-title":"Am J Neuroradiol"},{"key":"17170_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. 2016;15:155\u201363. https:\/\/doi.org\/10.1016\/j.jcm.2016.02.012.","journal-title":"J Chiropr Med"},{"key":"17170_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12880-025-01889-6","volume":"25","author":"L Schmidt","year":"2025","unstructured":"Schmidt L, Khadhraoui E, Klebingat S, Sandalcioglu IE, Schwab R, Neyazi B, et al. Late enhancement and wash-out maps for differentiation of glioblastoma and metastases. BMC Med Imaging. 2025;25:353. https:\/\/doi.org\/10.1186\/s12880-025-01889-6.","journal-title":"BMC Med Imaging"},{"key":"17170_CR25","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/jmri.26171","volume":"48","author":"SC Thust","year":"2018","unstructured":"Thust SC, Van Den Bent MJ, Smits M. Pseudoprogression of brain tumors. J Magn Reson Imaging. 2018;48:571\u201389. https:\/\/doi.org\/10.1002\/jmri.26171.","journal-title":"J Magn Reson Imaging"},{"key":"17170_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/01.nrl.0000080951.78533.c4","volume":"9","author":"P Giglio","year":"2003","unstructured":"Giglio P, Gilbert MR, Cerebral Radiation Necrosis. Neurologist. 2003;9:180\u20138. https:\/\/doi.org\/10.1097\/01.nrl.0000080951.78533.c4.","journal-title":"Neurologist"},{"key":"17170_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11060-024-04910-0","volume":"172","author":"H Chen","year":"2025","unstructured":"Chen H, Tan G, Zhong L, Hu Y, Han W, Huang Y, et al. MR perfusion characteristics of pseudoprogression in brain tumors treated with immunotherapy \u2013 a comparative study with chemo-radiation induced pseudoprogression and radiation necrosis. J Neurooncol. 2025;172:239\u201347. https:\/\/doi.org\/10.1007\/s11060-024-04910-0.","journal-title":"J Neurooncol"},{"key":"17170_CR28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/neuonc\/now148","volume":"19","author":"P Patel","year":"2017","unstructured":"Patel P, Baradaran H, Delgado D, Askin G, Christos P, John Tsiouris A, et al. MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. Neuro-Oncol. 2017;19:118\u201327. https:\/\/doi.org\/10.1093\/neuonc\/now148.","journal-title":"Neuro-Oncol"},{"key":"17170_CR29","doi-asserted-by":"publisher","first-page":"vdac027","DOI":"10.1093\/noajnl\/vdac027","volume":"4","author":"R Fu","year":"2022","unstructured":"Fu R, Szidonya L, Barajas RF, Ambady P, Varallyay C, Neuwelt EA. Diagnostic performance of DSC perfusion MRI to distinguish tumor progression and treatment-related changes: a systematic review and meta-analysis. Neuro-Oncol Adv. 2022;4:vdac027. https:\/\/doi.org\/10.1093\/noajnl\/vdac027.","journal-title":"Neuro-Oncol Adv"},{"key":"17170_CR30","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.21037\/qims-22-32","volume":"12","author":"J Zhang","year":"2022","unstructured":"Zhang J, Wang Y, Wang Y, Xiao H, Chen X, Lei Y, et al. Perfusion magnetic resonance imaging in the differentiation between glioma recurrence and pseudoprogression: a systematic review, meta-analysis and meta-regression. Quant Imaging Med Surg. 2022;12:4805\u201322. https:\/\/doi.org\/10.21037\/qims-22-32.","journal-title":"Quant Imaging Med Surg"},{"key":"17170_CR31","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/neuonc\/noaa141","volume":"22","author":"JL Boxerman","year":"2020","unstructured":"Boxerman JL, Quarles CC, Hu LS, Erickson BJ, Gerstner ER, Smits M, et al. Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. Neuro-Oncol. 2020;22:1262\u201375. https:\/\/doi.org\/10.1093\/neuonc\/noaa141.","journal-title":"Neuro-Oncol"},{"key":"17170_CR32","doi-asserted-by":"publisher","first-page":"111076","DOI":"10.1016\/j.ejrad.2023.111076","volume":"167","author":"N Nierobisch","year":"2023","unstructured":"Nierobisch N, Ludovichetti R, Kadali K, Fierstra J, H\u00fcllner M, Michels L, et al. Comparison of clinically available dynamic susceptibility contrast post processing software to differentiate progression from pseudoprogression in post-treatment high grade glioma. Eur J Radiol. 2023;167:111076. https:\/\/doi.org\/10.1016\/j.ejrad.2023.111076.","journal-title":"Eur J Radiol"},{"key":"17170_CR33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1148\/radiol.2017160150","volume":"284","author":"NR Boonzaier","year":"2017","unstructured":"Boonzaier NR, Larkin TJ, Matys T, Van Der Hoorn A, Yan J-L, Price SJ. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma. Radiology. 2017;284:180\u201390. https:\/\/doi.org\/10.1148\/radiol.2017160150.","journal-title":"Radiology"},{"key":"17170_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-026-07971-z","author":"T Zhang","year":"2026","unstructured":"Zhang T, Zhu H, Sun H, Chen Y, Sun X, Wu Y, et al. Radiomics in glioblastoma recurrence: advances in prediction, localization, and differentiation from treatment-related effects. J Transl Med. 2026. https:\/\/doi.org\/10.1186\/s12967-026-07971-z.","journal-title":"J Transl Med"},{"key":"17170_CR35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s12672-024-01266-9","volume":"15","author":"SJ M\u00fcller","year":"2024","unstructured":"M\u00fcller SJ, Khadhraoui E, Henkes H, Ernst M, Rohde V, Schatlo B, et al. Differentiation between multifocal CNS lymphoma and glioblastoma based on MRI criteria. Discov Oncol. 2024;15:397.","journal-title":"Discov Oncol"},{"key":"17170_CR36","doi-asserted-by":"publisher","unstructured":"Lin G, Ding W, Chen Y, Xiong L, Hong J, He P, et al. Gadolinium-free MR perfusion imaging based on generative adversarial network for primary intracranial tumor diagnosis: a multi-center study. Neuro-Oncol. 2026;noag144. https:\/\/doi.org\/10.1093\/neuonc\/noag144.","DOI":"10.1093\/neuonc\/noag144"},{"key":"17170_CR37","doi-asserted-by":"publisher","first-page":"e222471","DOI":"10.1148\/radiol.222471","volume":"308","author":"B Wang","year":"2023","unstructured":"Wang B, Pan Y, Xu S, Zhang Y, Ming Y, Chen L, et al. Quantitative Cerebral Blood Volume Image Synthesis from Standard MRI Using Image-to-Image Translation for Brain Tumors. Radiology. 2023;308:e222471. https:\/\/doi.org\/10.1148\/radiol.222471.","journal-title":"Radiology"},{"key":"17170_CR38","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/neuonc\/nou230","volume":"17","author":"L Zach","year":"2015","unstructured":"Zach L, Guez D, Last D, Daniels D, Grober Y, Nissim O, et al. Delayed contrast extravasation MRI: a new paradigm in neuro-oncology. Neuro-Oncol. 2015;17:457\u201365. https:\/\/doi.org\/10.1093\/neuonc\/nou230.","journal-title":"Neuro-Oncol"},{"key":"17170_CR39","doi-asserted-by":"publisher","first-page":"e52008","DOI":"10.1371\/journal.pone.0052008","volume":"7","author":"L Zach","year":"2012","unstructured":"Zach L, Guez D, Last D, Daniels D, Grober Y, Nissim O, et al. Delayed Contrast Extravasation MRI for Depicting Tumor and Non-Tumoral Tissues in Primary and Metastatic Brain Tumors. PLoS ONE. 2012;7:e52008. https:\/\/doi.org\/10.1371\/journal.pone.0052008.","journal-title":"PLoS ONE"},{"key":"17170_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3174\/ajnr.A6384","volume":"41","author":"H Maral","year":"2020","unstructured":"Maral H, Ertekin E, Tun\u00e7y\u00fcrek \u00d6, \u00d6zsunar Y. Effects of Susceptibility Artifacts on Perfusion MRI in Patients with Primary Brain Tumor: A Comparison of Arterial Spin-Labeling versus DSC. Am J Neuroradiol. 2020;41:255\u201361. https:\/\/doi.org\/10.3174\/ajnr.A6384.","journal-title":"Am J Neuroradiol"},{"key":"17170_CR41","doi-asserted-by":"publisher","first-page":"vdaf161","DOI":"10.1093\/noajnl\/vdaf161","volume":"7","author":"M Tahamtan","year":"2025","unstructured":"Tahamtan M, Afsharzadeh M, Sarvari M, Rahmani S, Geravandi M, Amiri D, et al. Contrast clearance analysis in neuro-oncology: A systematic review and meta-analysis on differentiating posttreatment changes from tumor progression. Neuro-Oncol Adv. 2025;7:vdaf161. https:\/\/doi.org\/10.1093\/noajnl\/vdaf161.","journal-title":"Neuro-Oncol Adv"},{"key":"17170_CR42","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1177\/19714009251324305","volume":"38","author":"H Alkhatatneh","year":"2025","unstructured":"Alkhatatneh H, Chen Y-H, Imhoff S, Fogel L, Yao K, Dubin D, et al. Evaluating the diagnostic ability of treatment response assessment maps (TRAMs)\/contrast clearance analysis (CCA) in predicting the presence of active brain tumors. Neuroradiol J. 2025;38:745\u201351. https:\/\/doi.org\/10.1177\/19714009251324305.","journal-title":"Neuroradiol J"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-17170-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-17170-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-17170-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:47:47Z","timestamp":1792108067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-17170-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["17170"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-17170-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"2 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Institutional Review Board of the University of Magdeburg (Leipziger Str. 44, D-39104 Magdeburg, Germany, No. 103\/24) approved this study, which adhered to the 2013 Helsinki Declaration. Owing to the retrospective and observational nature of the study, the ethics committee waived the requirement for informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1238"}}